Table 2.
Frequency distribution of cardiovascular disease and diabetes in different sex and age groups in patients with COVID-19.
| Variables | Age groups in years (%) |
P value | |||||||
|---|---|---|---|---|---|---|---|---|---|
| 0–9 | 10–19 | 20–29 | 30–39 | 40–49 | 50–59 | 60–69 | Above 70 | ||
| Sex | |||||||||
| Male | 3/526 (0.6) | 16/526 (3.0) | 123/526 (23.4) | 92/526 (17.5) | 101/526 (19.2) | 123/526 (23.4) | 55/526 (10.5) | 13/526 (2.5) | .013 |
| Female | 0/273 (0) | 13/273 (4.8) | 67/273 (24.5) | 50/273 (18.3) | 69/273 (25.3) | 46/273 (16.8) | 24/273 (8.8) | 4/273 (1.5) | .024 |
| Suffering from cardiovascular diseases (CVD) | |||||||||
| Yes | 0/337 (0) | 0/337 (0) | 7/337 (2.1) | 28/337 (8.3) | 90/337 (26.7) | 135/337 (40) | 63/337 (18.7) | 14/337 (4.2) | .001 |
| No | 2/462 (0.4) | 24/462 (5.2) | 152/462 (32.9) | 100/462 (21.7) | 88/462 (19.0) | 61/462 (13.2) | 29/462 (6.3) | 6/462 (1.3) | .043 |
| Suffering from diabetes | |||||||||
| Yes | 0/261 (0) | 1/261 (0.4) | 5/261 (1.9) | 20/261 (7.7) | 74/261 (28.4) | 92/261 (35.2) | 56/261 (21.5) | 13/261 (5.0) | .029 |
| No | 3/538 (0.6) | 28/538 (5.2) | 185/538 (34.4) | 122/538 (22.7) | 96/538 (17.8) | 77/538 (14.3) | 23/538 (4.3) | 4/538 (0.7) | .047 |
| Suffering from both diabetes and CVD | |||||||||
| Yes | 0/195 (0) | 0/195 (0) | 0/195 (0) | 2/195 (1) | 37/195 (18.9) | 82/195 (42.1) | 60/195 (30.7) | 14/195 (7.3) | .004 |
| No | 3/604 (0.5) | 25/604 (4.1) | 163/604 (27) | 121/604 (20) | 130/604 (21.5) | 110/604 (18.3) | 43/604 (7.1) | 9/604 (1.5) | .067 |
| Complication related with CVD increased after COVID-19 infection | |||||||||
| Yes | 0/131 (0) | 0/131 (0) | 3/131 (2.3) | 11/131 (8.4) | 33/131 (25.2) | 52/131 (39.7) | 27/131 (20.6) | 5/131 (3.8) | .050 |
| No | 3/668 (0.4) | 29/668 (4.3) | 187/668 (28.0) | 131/668 (19.6) | 137/668 (20.5) | 117/668 (17.5) | 52/668 (7.8) | 12/668 (1.8) | .034 |
| Complication related with diabetes increased after COVID-19 infection | |||||||||
| Yes | 0/114 (0) | 1/114 (0.9) | 3/114 (2.6) | 4/114 (3.5) | 28/114 (24.6) | 42/114 (36.8) | 30/114 (26.3) | 6/114 (5.3) | .731 |
| No | 3/685 (0.4) | 28/685 (4.1) | 187/685 (27.3) | 138/685 (20.1) | 142/685 (20.7) | 127/685 (18.5) | 49/685 (7.2) | 11/685 (1.6) | .468 |
| Symptoms of CVD and diabetes worsen after COVID-19 infection | |||||||||
| Yes | 0/52 (0) | 0/52 (0) | 0/52 (0) | 1/52 (1.9) | 6/52 (11.5) | 24/52 (46.2) | 18/52 (34.6) | 3/52 (5.8) | .389 |
| No | 3/747 (0.4) | 29/747 (3.9) | 190/747 (25.4) | 141/747 (18.9) | 164/747 (22.0) | 145/747 (19.4) | 61/747 (8.2) | 14/747 (1.9) | .347 |
| Fatality in patients with CVD and COVID-19 | |||||||||
| Yes | 1/288 (0.3) | 3/288 (1.0) | 53/288 (18.4) | 47/288 (16.3) | 71/288 (24.7) | 75/288 (26.0) | 31/288 (10.8) | 7/288 (2.4) | .046 |
| No | 2/511 (0.4) | 26/511 (5.1) | 137/511 (26.8) | 95/511 (18.6) | 99/511 (19.4) | 94/511 (18.4) | 48/511 (9.4) | 10/511 (2.0) | .017 |
| Fatality in patients with diabetes and COVID-19 | |||||||||
| Yes | 1/237 (0.4) | 3/237 (1.3) | 46/237 (19.4) | 39/237 (16.5) | 55/237 (23.2) | 62/237 (26.2) | 24/237 (10.1) | 7/237 (3.0) | .056 |
| No | 2/562 (0.4) | 26/562 (4.6) | 144/562 (25.6) | 103/562 (18.3) | 115/562 (20.5) | 107/562 (19.0) | 55/562 (9.8) | 10/562 (1.8) | .049 |
| Fatality in patients with diabetes, CVD and COVID-19 | |||||||||
| Yes | 1/184 (0.5) | 1/184 (0.5) | 38/184 (20.7) | 22/184 (12.0) | 48/184 (26.1) | 48/184 (26.1) | 21/184 (11.4) | 5/184 (2.7) | .049 |
| No | 2/615 (0.3) | 28/615 (4.6) | 152/615 (24.7) | 120/615 (19.5) | 122/615 (19.8) | 121/615 (19.7) | 58/615 (9.4) | 12/615 (2.0) | .028 |
| Treatment problems during COVID-19 | |||||||||
| Yes | 0/124 (0) | 1/124 (0.8) | 2/124 (1.6) | 11/124 (8.9) | 30/124 (24.2) | 47/124 (37.9) | 29/124 (23.4) | 4/124 (3.2) | .769 |
| No | 3/675 (0.4) | 28/675 (4.1) | 188/675 (27.9) | 131/675 (19.4) | 140/675 (20.7) | 122/675 (18.1) | 50/675 (7.4) | 13/675 (1.9) | .083 |
P value < .05 were statistically significant.